Activated Vitamin D trial

Free download John’s textbooks in high res pdf. Order my Physiology Notes in hard copy if you live in the UK, The effect of 1-hydroxy-vitamin D treatment in hospitalized patients with COVID-19: A retrospective study Vitamin D deficiency is associated with elevated risk, severity, and mortality Asthma, tuberculosis, chronic pulmonary obstructive disease (COPD), and viral respiratory infections Consistent paper 1. Vitamin D and its therapeutic relevance in pulmonary diseases Vitamin D essential for several cellular processes, wound healing, immunity inflammation Studies have displayed strong inter-relations with vit D deficiency and progression of lung disorders Its ease of supplementation and development of personalized medicine, could lead us to an effective adjunct and cost-effective method of therapeutic modality for highly fatal pulmonary diseases. Consistent paper 2. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19, consider taking 10,000 IU/d of vitamin D3 for a few weeks to rapidly raise 25(OH)D concentrations, followed by 5000 IU/d. The goal should be to raise 25(OH)D concentrations above 40–60 ng/mL (100–150 nmol/L). For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful. Vitamin D deficiency is relatively common Especially among the elderly, the obese, and patients with comorbidities including hypertension, diabetes, COPD, and CKD Vitamin D induces Production of antiviral peptides (defensins), especially in the respiratory epithelium Vitamin D upregulates anti-inflammatory cytokines such as interleukin-10 (IL-10), and downregulates pro-inflammatory cytokines including IL-1, IL-6, and tumor necrosis factor alfa Vitamin D effects angiotensin-converting enzyme axis, which has a protective effect against ARDS Efficacy of activated vitamin D supplementation in coronavirus disease 2019 (COVID-19) 1-hydroxy-vitamin D was prescribed on day 1 or 2 (median duration 8 days) To evaluate the effect of 1-hydroxy-vitamin D, on the prevention of severe disease and mortality, in patients hospitalized for COVID-19. Retrospective study, April 2021 and October 2021 Primarily Delta variant Hospitalised 312 patients with COVID-19 Between July 2022 and September 2022 Primarily Omicron variant Serum 25-hydroxyvitamin D (25(OH)D) levels measured at admission 1-hydroxy-vitamin D was prescribed Primary composite endpoints Need for additional respiratory support Need for high-flow oxygen therapy or invasive mechanical ventilation In-hospital mortality rate. Experimental group (n = 122) Given 1-hydroxy-vitamin D Median age, 66 Baseline vitamin D deficient, 77% Control group ( n = 190) Median age, 58 Age difference (p = ) Baseline vitamin D deficient, 65% Baseline D deficiency (p = ) (defined as serum 25(OH)D level less than 20 ng/mL) Proportion of those requiring more respiratory support and in-hospital mortality Vit D group, 6% Control group,14% (p = ) After propensity score matching (to reduce bias caused by confounding variables) (P = log-rank test) Proportion of patients who received high flow oxygen Vit D group 4% Control group, 11% (P = ) In-hospital mortality Vit D group, 3% Control group, 5% (P = 0.3). Need for additional respiratory support Vit D group, 6% Control group, 14% (P = ) Conclusions 1-hydroxy-vitamin treatment may improve outcomes in hospitalized patients with COVID- 19, reducing composite outcomes including the need for additional respiratory support and in-hospital mortality.